Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

PRESS RELEASE: MIG AG records 2020 as the most successful year in its company history and aims at further growth

04/27/2021 | 03:01am EDT
DGAP-News: MIG Verwaltungs AG / Key word(s): Annual Report 
MIG AG records 2020 as the most successful year in its company history and aims at further growth 
2021-04-27 / 09:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
MIG AG records 2020 as the most successful year in its company history and aims at further growth 
  . Total payouts to MIG investors increased to EUR 900 million 
  . Portfolio company BioNTech sees groundbreaking success with first-ever approval of mRNA vaccine 
  . Immatics becomes second portfolio company to list on Nasdaq 
  . Additional portfolio companies validated by significant financing rounds 
  . Portfolio expanded with investments in Temedica, Neracare, Innatera and German Bionic 
  . MIG Fonds invests total of EUR 46 million in new and existing companies 
  . New investments and successes of current portfolio companies illustrate strong momentum for 2021 
Munich, Germany, 27 April 2021 
MIG Verwaltungs AG (MIG AG), one of the leading German VC investors, and its funds (MIG Fonds) look back on the most 
successful year in the history of the company. In particular, a record distribution of EUR600 million to investors from 
its stake in the biotech company BioNTech contributed to this landmark year. The 2020 distribution to MIG Fonds 
investors brings the total payout to about EUR 900 million. By the end of 2020, MIG Fonds had invested almost EUR 600 
million in over 40 promising young deep tech and biotech business models. 
Michael Motschmann, General Partner of MIG AG, explains: "The outstanding performance of BioNTech and its founders Dr. 
Özlem Türeci and Prof. Ugur Sahin in the development, manufacturing and marketing of the first approved vaccine against 
Covid-19 resulted in very positive growth of BioNTech SE's stock price. We used this to realize considerable profits 
for our investors through partial exits." Several MIG Fonds were among the founding investors of BioNTech, listed on 
Nasdaq since October 2019. 
One of the most important events in 2020 came in July with the first day of trading on Nasdaq for portfolio company 
Immatics. It was the first listing of a European biotech company undertaken through a Special-Purpose Acquisition 
Company ("SPAC"). This was the fourth public offering of a MIG Fonds portfolio company after BRAIN, NFON and BioNTech. 
Last year, MIG AG added a number of new, highly innovative companies to its investment funds: 
- In January 2020, MIG Fonds no. 2, 8, 10, 12 and 16 made an initial investment of EUR 6 million in Temedica, a digital 
healthcare start-up developing and marketing therapy-related smartphone apps. 
- In March 2020, MIG Fonds no. 10, 14 and 16 contributed around EUR 3 million to an A-round funding for Neracare, a 
precision medicine specialist for skin cancer risk assessment. 
- November 2020 featured a seed financing for Innatera Nanosystems, to which MIG Fonds no. 8 and 16, among others, 
contributed around EUR 1.25 million. The Dutch start-up, a spin-off from the renowned Delft University of Technology, is 
developing a fundamentally new chip architecture for energy-efficient applications of artificial intelligence (AI). 
- German Bionic was the fourth new investment in 2020, in which MIG Fonds no. 8 and 16 participated with a total of EUR 4 
million. German Bionic is an already established robotics specialist for exoskeletons. Other leading international 
investors took part in the EUR 20 million A-round financing in addition to MIG. 
In 2020, additional portfolio companies completed successful financing rounds with a total volume of EUR 170 million. 
From MIG Fonds alone, MIG portfolio companies received a total of about EUR 46 million in new investments and 
refinancing. Overall, the majority of portfolio companies achieved major progress in advancing their respective 
technologies and business models. 
In the first quarter of 2021, MIG portfolio companies recorded several important successes. The Tübingen-based 
biotechnology company Immatics published excellent clinical study data from a highly innovative cancer therapy. 
"Results like these once again highlight the potential of innovative technology companies which, if successfully 
developed, can help solve fundamental problems in medicine, the environment and other areas critical to a better 
future," says Michael Motschmann. "In our deal flow, we have purposefully supplemented our portfolio with young, highly 
innovative companies that aim to play a leading role in future markets. We invested in specialist companies in the life 
sciences, digitization and artificial intelligence, which map essential future trends. Having already invested in a 
Danish and a Finnish start-up in 2019, we have increased our international allocation with additional investments in 
non-German-speaking countries in 2020." 
At the beginning of 2021, two new portfolio companies were added: Creative Balloons (medical technology) and the French 
start-up Zadient Technologies (new materials / semiconductors). 
Michael Motschmann explains the goals for 2021: "The maturity of certain portfolio companies has given us an 
opportunity to realize significant gains for our investors in the current fiscal year. At the same time, we want to 
increase the value of our overall portfolio by working closely with current management teams while keeping an eye out 
for other interesting young companies." 
About MIG AG 
MIG Verwaltungs AG (MIG AG), Munich, is one of the leading German VC investors. MIG invests through MIG Fonds in young, 
deep tech and life science companies in German-speaking Europe and beyond. To date, the company has invested more than 
EUR 600 million in over 40 companies. MIG's portfolio companies develop innovations in biopharmaceuticals, AI / machine 
learning, quantum technologies, digitization / IoT, medtech and digital health. The MIG investment portfolio currently 
consists of 30 companies. 
MIG's investment team consists of a committed group of experts including engineers, scientists and investors who use 
analytical and creative processes to evaluate the risks and opportunities of business models and technologies. Their 
reputation, experience and network enable excellent access to companies, institutions and decision-makers which 
supports the growth of their portfolio companies. 
In recent years, MIG AG has successfully sold its portfolio companies SuppreMol (to Baxter in 2015), sunhill 
technologies (to Volkswagen in 2015), Ganymed (to Astellas in 2016) and Siltectra (to Infineon in 2018) and leads Brain 
(in 2017), NFON (in 2018), BioNTech (in 2019) and Immatics (in 2020) to listings on stock exchanges. 
For further information please visit: www.mig.ag/en/, www.mig-fonds.de 
Contact: 
MC Services 
Julia Hofmann 
+49-89-210228-0 
migag@mc-services.eu 
=---------------------------------------------------------------------------------------------------------------------- 
2021-04-27 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1188221 2021-04-27

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1188221&application_name=news 
 

(END) Dow Jones Newswires

April 27, 2021 03:00 ET (07:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. -0.49% 1912 End-of-day quote.19.95%
BIONTECH SE -0.79% 284 Delayed Quote.251.15%
DJ INDUSTRIAL -0.24% 35058.52 Delayed Quote.14.56%
IMMATICS N.V. -0.58% 12.05 Delayed Quote.12.33%
INFINEON TECHNOLOGIES AG -2.84% 31.325 Delayed Quote.2.71%
NASDAQ COMP. -1.21% 14660.575708 Delayed Quote.15.12%
VOLKSWAGEN AG -2.13% 202.5 Delayed Quote.35.74%
Latest news "Companies"
05:09pFIRST BUSEY CORP /NV/ : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05:09pCHEMED CORP : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
05:09pFIRST COMMONWEALTH FINANCIAL CORP /PA/ : Results of Operations and Financial Condition (form 8-K)
AQ
05:09pRENASANT CORP : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05:09pARCBEST : « Declares an $0.08/Share Quarterly Dividend
PR
05:09pFinancials Fall With Treasury Yields -- Financials Roundup
DJ
05:08pMASIMO : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05:08pSEVERN BANCORP INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
05:08pBROWN & BROWN : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05:08pLA JOLLA PHARMACEUTICAL CO : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Latest news "Companies"